KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBT: 2015-2025

Historic EBT for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $147.2 million.

  • BeOne Medicines' EBT rose 249.70% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.3 million, marking a year-over-year increase of 122.83%. This contributed to the annual value of -$533.0 million for FY2024, which is 35.46% up from last year.
  • BeOne Medicines' EBT amounted to $147.2 million in Q3 2025, which was up 47.83% from $99.5 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' EBT registered a high of $229.3 million during Q3 2023, and its lowest value of -$606.0 million during Q4 2021.
  • Moreover, its 3-year median value for EBT was -$98.3 million (2024), whereas its average is -$99.2 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 780.92% in 2022, then surged by 249.70% in 2025.
  • Quarterly analysis of 5 years shows BeOne Medicines' EBT stood at -$606.0 million in 2021, then rose by 28.89% to -$431.0 million in 2022, then increased by 18.61% to -$350.8 million in 2023, then surged by 75.67% to -$85.4 million in 2024, then surged by 249.70% to $147.2 million in 2025.
  • Its EBT stands at $147.2 million for Q3 2025, versus $99.5 million for Q2 2025 and $20.9 million for Q1 2025.